Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$309.44M+21.0%-$288.28M+38.1%-$289.13M+44.3%-$281.9M+44.8%-$391.59M+11.9%
$1.51M+15.8%$1.51M+37.4%$1.48M+68.8%$1.42M+99.0%$1.31M+129%
$111.22M+37.5%$98.13M+22.8%$90.02M+16.8%$81.66M+13.7%$80.91M+38.6%
-$307.41M+31.5%-$395.31M-1.5%
$1.05M-54.3%$974K-47.7%$1.11M-38.6%
-$38.61M+90.0%-$208.56M+22.1%
$249.67M+46.9%$255.98M-65.2%$266.8M-77.7%$37.61M-96.9%$170M-84.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Madrigal Pharmaceuticals, Inc. generate?
Madrigal Pharmaceuticals, Inc. (MDGL) generated -$436.8M in operating cash flow over the trailing twelve months.
What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
After $4.7M of capital expenditures, Madrigal Pharmaceuticals, Inc.'s free cash flow was -$440.3M over the trailing twelve months, up 3.7% year over year.
Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.